🚀 Exciting milestone for GENSPEED! Together with CEPI (Coalition for Epidemic Preparedness Innovations) we’re developing rapid analytical tools to make vaccine quality control faster and more accessible worldwide.
📢 New CEPI-funded project seeks to speed up key vaccine manufacture analytics that ensure every vaccine batch is safe, consistent, cost-effective and high quality in an epidemic or pandemic response. Analytics function as the backbone of a fast, scalable, and safe vaccine manufacturing process. Yet current testing methods can be slow, resource-intensive, and prone to human error, risking delays in vaccine release when speed matters most. That’s why, with up to US$197,602 in CEPI funding, we’re partnering with Austria’s GENSPEED Biotech GmbH. The project aims to repurpose its GENSPEED R2 point-of-care diagnostic device to create a fast, fully automated quality control test for detecting residual HEK293 host cell proteins — a critical step in ensuring vaccine safety and consistency. The technology could deliver results in just 20 minutes, compared to the four hours typically required by current methods. By automating complex laboratory processes and reducing dependence on specialised staff, this innovation could cut development timelines, lower costs, and make high-quality vaccine testing more accessible worldwide. Through projects like this, CEPI is strengthening global capacity to produce safe vaccines at speed in support of CEPI’s 100 Days Mission.